Midwives Advocate for Faster Menopause Care as Women’s Health Gaps Widens

Swedish midwives are advocating for expanded prescribing authority to address a critical gap in menopausal care, as recent reports reveal systemic failures in supporting women through the climacteric transition. With over 70% of Swedish women experiencing moderate to severe vasomotor symptoms during perimenopause—yet fewer than 30% receiving guideline-concordant treatment—midwives argue their frontline position uniquely qualifies them to initiate hormone therapy after appropriate training. This proposal emerges against a backdrop of rising morbidity linked to untreated menopause, including increased cardiovascular risk and osteoporosis-related fractures, prompting urgent calls for clinical pathway reform.

Key Clinical Takeaways:

• Untreated menopausal symptoms affect over two-thirds of Swedish women, contributing to avoidable long-term health risks including hypertension and bone density loss.
• Midwives, already managing perinatal and reproductive health, are positioned to deliver timely hormone therapy following standardized training protocols.
• Expanding midwifery scope could reduce diagnostic delays and align Sweden with evolving WHO recommendations for integrated menopausal care in primary settings.

The core issue lies not in a lack of effective treatments—transdermal estradiol and micronized progesterone remain first-line for vasomotor symptoms per NICE and Endocrine Society guidelines—but in fragmented access to care. Current Swedish healthcare models often require multiple referrals to gynecologists or endocrinologists, creating wait times averaging 4–6 months in regional clinics. During this delay, women face heightened risk of metabolic syndrome, with longitudinal data from the Karolinska Institutet showing a 22% increased incidence of new-onset hypertension among untreated perimenopausal women over five years (n=12,400, BMJ, 2023). Meanwhile, midwives routinely manage complex hormonal transitions in pregnancy and postpartum, yet regulatory barriers prevent them from prescribing menopausal hormone therapy (MHT) despite demonstrated competency in risk assessment and patient counseling.

Internationally, similar expansions have shown promise. In the UK, nurse independent prescribers managing menopause in community clinics achieved 89% patient satisfaction and reduced GP referrals by 40% in a 2022 service evaluation (BJGP). Crucially, safety outcomes remained equivalent to physician-led care, with no increase in thromboembolic events or endometrial hyperplasia when prescribing adhered to UKMS guidelines. This evidence informs the Swedish proposal, which advocates for a tiered certification pathway requiring 40 hours of didactic training plus supervised clinical practicum—modeled after the Swedish Society of Obstetrics and Gynecology’s existing perinatal mental health prescribing program.

“Midwives are already trusted advisors for women navigating hormonal flux. Denying them prescribing authority for menopause ignores both their clinical readiness and the lived reality of patients falling through systemic cracks.”

Funding for the proposed training initiative would initially reach from a regional innovation grant administered by Västmanland County Council, with plans to seek national scaling support from Forte (Swedish Research Council for Health, Working Life and Welfare) pending pilot outcomes. Transparency is essential: no pharmaceutical industry funding is involved in the advocacy effort, which remains clinician-led and grounded in implementation science. The approach prioritizes patient-centered outcomes over drug promotion, aligning with WHO’s 2021 guidance on strengthening midwifery roles in non-communicable disease management.

For women navigating perimenopausal symptoms, timely access to care is not merely convenient—it is clinically consequential. Delayed intervention correlates with accelerated bone loss, with studies showing up to 2% annual lumbar spine density reduction in untreated early perimenopause (JCEM, 2021). Untreated vasomotor symptoms persist for a median of 7.4 years, significantly impacting quality of life and workplace productivity. Empowering midwives to prescribe MHT represents a pragmatic, evidence-based strategy to close the treatment gap without compromising safety.

Patients experiencing persistent hot flashes, night sweats, or mood disturbances should consider consulting certified menopause practitioners for comprehensive evaluation. Simultaneously, healthcare administrators seeking to implement expanded midwifery prescribing models may benefit from guidance offered by healthcare compliance attorneys familiar with Nordic scope-of-practice reforms. For diagnostic clarity regarding bone health or cardiovascular risk assessment, referral to accredited imaging centers equipped for DEXA scanning and carotid intima-media thickness testing remains advisable.

As Sweden debates this scope expansion, the underlying principle is clear: menopausal care must evolve beyond episodic crisis management toward proactive, accessible, and continuous support. The evidence supports midwives as capable partners in this endeavor—not as replacements for physicians, but as essential extensions of a strained system striving to meet women’s health needs with both competence and compassion.

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*